ArticleInflammatory bowel diseases2015
IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function.
Article in Inflammatory bowel diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 55 citations in OpenAlex.
- Enterotoxigenic Bacteroides fragilis Induces Host Genotype-Specific Colonic Epithelial and Immune Responses in Mice.The Journal of infectious diseases · 2026Article
- IL-1 family of cytokines in gastrointestinal and liver disorders.Nature reviews. Gastroenterology & hepatology · 2026Review
- Air-liquid intestinal cell culture allowsAPL bioengineering · 2024Article
- A Deep View of the Biological Property of Interleukin-33 and Its Dysfunction in the Gut.International journal of molecular sciences · 2023Review
- Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study.Diagnostics (Basel, Switzerland) · 2023Article
- Pathophysiology of Inflammatory Bowel Disease: Innate Immune System.International journal of molecular sciences · 2023Review
- IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infection.Nature communications · 2022Article
- Review
- Could Chronic Rhinosinusitis Increase the Risk of Ulcerative Colitis? A Nationwide Cohort Study.Diagnostics (Basel, Switzerland) · 2022Article
- Heterogeneity of ILC2s in the Intestine; Homeostasis and Pathology.Frontiers in immunology · 2022Review
- Host/microbiota interactions in health and diseases-Time for mucosal microbiology!Mucosal immunology · 2021Review
- IL-33 is produced by colon fibroblasts and differentially regulated in acute and chronic murine colitis.Scientific reports · 2021Article
- Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3β-mediated restriction of epithelial IL-33.Nature communications · 2021Article
- Interleukin (IL)-33 is dispensable for Schistosoma mansoni worm maturation and the maintenance of egg-induced pathology in intestines of infected mice.Parasites & vectors · 2021Article
- Role of Goblet Cells in Intestinal Barrier and Mucosal Immunity.Journal of inflammation research · 2021Review
- IL-33 Drives Expansion of Type 2 Innate Lymphoid Cells and Regulatory T Cells and Protects Mice From Severe, Acute Colitis.Frontiers in immunology · 2021Article
- Review
- Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis.Clinical & translational immunology · 2020Review
- Perturbations to Homeostasis in Experimental Models Revealed Innate Pathways Driving Food Allergy.Frontiers in immunology · 2020Review
- 3D bioengineered tissue model of the large intestine to study inflammatory bowel disease.Biomaterials · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundIL-33, a member of the IL-1 cytokine family that signals through ST2, is upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL-33 augments type 2 immune responses, which have been implicated in UC pathogenesis. We sought to determine the role of IL-33 signaling in oxazolone (OXA) colitis, a type 2 cytokine-mediated murine model of UC.
methodsColon mucosal IL-33 expression was compared between pediatric and adult UC and non-IBD patients using immunohistochemistry and real-time PCR. OXA colitis was induced in WT, IL-33, and ST2 mice, and histopathology, cytokine levels, and goblet cells were assessed. Transepithelial resistance was measured across IL-33-treated T84 cell monolayers.
resultsColon mucosal IL-33 was increased in pediatric patients with active UC and in OXA colitis. IL-33 and ST2 OXA mice exhibited increased disease severity compared with WT OXA mice. OXA induced a mixed mucosal cytokine response, but few differences were observed between OXA WT and IL-33 or ST2 mice. Goblet cells were significantly decreased in IL-33 and ST2 OXA compared with WT OXA mice. IL-33 augmented transepithelial resistance in T84 cells, and this effect was blocked by the ERK1/2 inhibitor PD98,059.
conclusionsOXA colitis is exacerbated in IL-33 and ST2 mice. Increased mucosal IL-33 in human UC and murine colitis may be a homeostatic response to limit inflammation, potentially through effects on epithelial barrier function. Further investigation of IL-33 protective mechanisms would inform the development of novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.